9-([1,1′-biphenyl]-3-yl)-3-bromo-9H-carbazole | CAS:1428551-28-3

We serve 9-([1,1′-biphenyl]-3-yl)-3-bromo-9H-carbazole CAS:1428551-28-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
9-([1,1'-biphenyl]-3-yl)-3-bromo-9H-carbazole

Chemical Name:9-([1,1'-biphenyl]-3-yl)-3-bromo-9H-carbazole
CAS.NO:1428551-28-3
Synonyms:9-(3-Biphenylyl)-3-bromocarbazole
9-[1,1'-Biphenyl]-3-yl-3-bromo carbazole
3-Bromo-9-([1,1'-biphenyl]-3-yl)carbazole
Molecular Formula:C24H16BrN
Molecular Weight:398.29500
 
Physical and Chemical Properties:
Melting point:24ºC
Boiling point:126ºC
Flash point:73ºC
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 9-([1,1′-biphenyl]-3-yl)-3-bromo-9H-carbazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Bromo-9-([1,1′-biphenyl]-3-yl)carbazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Bromo-9-([1,1′-biphenyl]-3-yl)carbazole Use and application,9-([1,1′-biphenyl]-3-yl)-3-bromo-9H-carbazole technical grade,usp/ep/jp grade.


Related News: Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs.4-nitro-m-cresol manufacturer Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs.2-Aminoacetophenone hydrochloride supplier Such was the apparent demand sparked by the notice that the compound formula sold out on some stores on China’s e-commerce platform Taobao.3-chloropyridine-2-carboxylic acid vendor The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.